尿路上皮癌的临床病理学特征
收稿日期: 2023-02-14
网络出版日期: 2023-11-17
基金资助
江苏省第十六批六大人才高峰项目(WSN-043);江苏省第六期333高层次人才项目[(2022)3-28-020];江苏省青年医学重点人才项目(QNRC2016918)
Clinicopathological features of urothelial carcinoma
Received date: 2023-02-14
Online published: 2023-11-17
目的:探讨膀胱尿路上皮癌(urinary bladder urothelial carcinoma, UBUC)及上尿路上皮癌(upper tract urothelial carcinoma, UTUC)患者的临床病理特征,并分析预后。方法:随机选取2017年5月至2020年2月东部战区总医院及南京大学医学院附属鼓楼医院收治的115例尿路上皮癌(urothelial carcinoma, UC)患者,其中UBUC 80例,UTUC 35例。回顾性分析其临床资料,利用χ2检验和Fisher精确检验分析两者的临床病理特征差异,利用Kaplan-Meier法及Log-rank检验进行生存分析,并采用Cox比例风险模型进行多因素分析。结果:与UBUC组比较,UTUC患者中,女性患者更常见(28.6%比10.0%, P=0.012),而UTUC患者则更少发生神经侵犯(5.7%比33.7%, P=0.002)及血管侵犯(20.0%比45.0%, P=0.011),UTUC患者伴发原位癌也更为少见(2.9%比23.7%, P=0.007)。UBUC的组织学变异型主体为微乳头分化(31.3%)、鳞状分化(25.0%)和腺样分化(12.6%);而UTUC多见差分化癌(33.3%)、肉瘤样分化(22.2%)及神经内分泌分化(22.2%)。生存分析显示,UTUC患者的3年总生存率(overall survival, OS)略高于UBUC(81.8%比73.8%),但差异尚无统计学意义(P>0.05)。神经侵犯、血管侵犯、临床分期、淋巴结转移与UC患者的总生存期(overall survival,OS)相关,且血管侵犯和神经侵犯是UC患者总生存期的独立预测因子。结论:相较UBUC,UTUC女性构成比明显高于男性;UBUC则更易发生神经侵犯及血管侵犯、伴发原位癌。两者的预后并无明显差异。血管侵犯及神经侵犯是UC患者OS的独立预后因子。
周晓蝶, 陈巍魏, 余波, 王璇, 王建军, 石群立, 饶秋, 鲍炜 . 尿路上皮癌的临床病理学特征[J]. 诊断学理论与实践, 2023 , 22(03) : 292 -299 . DOI: 10.16150/j.1671-2870.2023.03.13
Objective: This paper aims to investigate the clinicopathological features of bladder cancer (UBUC) and upper urinary tract cancer (UTUC). Methods: A total of 115 patients with urothelial carcinoma (UC) admitted to Jinling Hospital and Nanjing Drum Tower Hospital from May 2017 to February 2020 were randomly selected and retrospectively analyzed, including 80 cases of UBUC and 35 cases of UTUC. The differences in clinicopathological characteristics between the two groups were analyzed by chi-square test and Fisher’s exact test. Kaplan-Meier method and Log-rank test were used for survival analysis, and Cox proportional hazards model was used for multivariate analysis. Results: Female patients were more common in UTUC (28.6% vs. 10.0%, P=0.012). UBUC was more likely to have neural invasion (33.7% vs.5.7%, P=0.002), vascular invasion (45.0% vs. 20.0%, P=0.011), and carcinoma in situ (23.7% vs. 2.9%, P=0.007). The main histological variants of UBUC were micropapillary differentiation (31.3%), squamous differentiation (25.0%) and adenoid differentiation (12.6%), while poorly differentiated carcinoma (33.3%), sarcomatoid differentiation (22.2%) and neuroendocrine differentiation (22.2%) were more common in UTUC. Survival analysis showed that there was no significant difference in overall survival (OS) between UTUC and UBUC (P>0.05). Neural invasion, vascular invasion, clinical stage, and lymph node metastasis are associated with OS in UC, and vascular invasion and neural invasion are independent predictors of overall survival in UC. Conclusions: Compared with UBUC, the incidence of UTUC in women is significantly higher than that in men, while UBUC is more likely to have neural invasion, vascular invasion and carcinoma in situ. Histological variants of UBUC are micropapillary, squamous and adenoid, while UTUC is mostly poorly differentiated carcinoma, sarcomatoid and neuroendocrine differentiation. There is no significant difference in prognosis between the two groups. Vascular invasion and neural invasion are significant predictors of UC-OS.
[1] | MARGULIS V, SHARIAT S F, MATIN S F, et al. Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration[J]. Cancer, 2009, 115(6):1224-1233. |
[2] | SHARIAT S F, FAVARETTO R L, GUPTA A, et al. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma[J]. World J Urol, 2011, 29(4):481-486. |
[3] | GANDAGLIA G, BIANCHI M, TRINH Q D, et al. Survival after nephroureterectomy for upper tract urothelial carcinoma: a population-based competing-risks analysis[J]. Int J Urol, 2014, 21(3):249-256. |
[4] | BABJUK M, BURGER M, CAPOUN O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)[J]. Eur Urol, 2022, 81(1):75-94. |
[5] | LUGHEZZANI G, BURGER M, MARGULIS V, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature[J]. Eur Urol, 2012, 62(1):100-114. |
[6] | RICHTERS A, ABEN K K H, KIEMENEY L A L M. The global burden of urinary bladder cancer: an update[J]. World J Urol, 2020, 38(8):1895-1904. |
[7] | CUMBERBATCH M G, ROTA M, CATTO J W, et al. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks[J]. Eur Urol, 2016, 70(3):458-466. |
[8] | XYLINAS E, RINK M, ROBINSON B D, et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy[J]. Eur J Cancer, 2013, 49(8):1889-1897. |
[9] | HUMPHREY P A, MOCH H, CUBILLA A L, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours[J]. Eur Urol, 2016, 70(1):106-119. |
[10] | VESKIM?E E, ESPINOS E L, BRUINS H M, et al. What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? a european association of urology muscle invasive and metastatic bladder cancer guidelines panel systematic review[J]. Eur Urol Oncol, 2019, 2(6):625-642. |
[11] | GENITSCH V, KOLLáR A, VANDEKERKHOVE G, et al. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer[J]. Urol Oncol, 2019, 37(11):826-836. |
[12] | MORI K, JANISCH F, PARIZI M K, et al. Prognostic value of variant histology in upper tract urothelial carcinoma treated with nephroureterectomy: a systematic review and meta-analysis[J]. J Urol, 2020, 203(6):1075-1084. |
[13] | KIM J K, MOON K C, JEONG C W, et al. Variant histo-logy as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma[J]. Urol Oncol, 2017, 35(7):458,e9-e15. |
[14] | ZAMBONI S, FOERSTER B, ABUFARAJ M, et al. Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy[J]. BJU Int, 2019, 124(5):738-745. |
[15] | SHIBING Y, TURUN S, QIANG W, et al. Effect of concomitant variant histology on the prognosis of patients with upper urinary tract urothelial carcinoma after radical nephroureterectomy[J]. Urol Oncol, 2015, 33(5):204,e9-e16. |
[16] | LOPEZ-BELTRAN A, HENRIQUES V, MONTIRONI R, et al. Variants and new entities of bladder cancer[J]. Histopathology, 2019, 74(1):77-96. |
[17] | 崔庆敖, 覃茂, 张伟阳, 等. 机器人辅助腹腔镜根治性肾输尿管切除术治疗非转移性高危上尿路尿路上皮癌的疗效分析[J]. 重庆医科大学学报, 2022, 47(4):439-443. |
[17] | CUI Q A, QIN M, ZHANG W Y, et al. Efficacy analysis of robot-assisted radical nephroureterectomy and laparoscopic radical nephroureterectomy for non-metastatic high-risk upper tract urothelial carcinoma[J]. J Chongqing Med Univ, 2022, 47(4):439-443. |
[18] | SCOSYREV E, NOYES K, FENG C, et al. Sex and racial differences in bladder cancer presentation and mortality in the US[J]. Cancer, 2009, 115(1):68-74. |
[19] | ZHANG L, WU B, ZHA Z, et al. Concomitant carcinoma in situ may not be a prognostic factor for patients with bladder cancer following radical cystectomy: a PRISMA-compliant systematic review and meta-analysis[J]. World J Urol, 2020, 38(1):129-142. |
[20] | REDROW G, GUO C C, BRAUSI M A, et al. Upper urinary tract carcinoma in situ: current knowledge, future direction[J]. J Urol, 2017, 197(2):287-295. |
[21] | SU X, TANG Q, FANG D, et al. Comparisons of prognosis between urothelial carcinoma of the upper urinary tract and bladder with pT3-4 cancer[J]. Int J Clin Exp Med, 2016, 9(9):18308-18315. |
[22] | SATHIANATHEN N J, RISK M C, KONETY B R. Lymphadenectomy for muscle-invasive bladder cancer and upper tract urothelial cell carcinoma[J]. Urol Clin North Am, 2018, 45(2):215-228. |
[23] | SHARIAT S F, KARAKIEWICZ P I, PALAPATTU G S, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the bladder cancer research consortium[J]. J Urol, 2006, 176(6 Pt 1):2414-2422. |
[24] | ABDOLLAH F, SUN M, SCHMITGES J, DJAHANGIRIAN O, et al. Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy[J]. BJU Int, 2012, 109(8):1147-1154. |
[25] | MASON R J, KASSOUF W, BELL D G, et al. The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience[J]. Urology, 2012, 79(4):840-845. |
[26] | CROZIER J, PAPA N, PERERA M, et al. Lymph node yield in node-negative patients predicts cancer specific survival following radical cystectomy for transitional cell carcinoma[J]. Investig Clin Urol, 2017, 58(6):416-422. |
/
〈 |
|
〉 |